Article
Celgene repeatedly raised Revlimid's price to hit aggressive sales targets, congressional probe fi
Rating:
0.0
Views:
54
Likes:
1
Library:
1
Pharma has routinely defended its price hikes by arguing that research is risky and expensive, and rebates to middlemen are growing. But a congressional probe unveiled Wednesday shows Celgene, now part of Bristol Myers Squibb, had another reason for hiking Revlimid's price: meeting its revenue goals.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value